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Abstract
Rationale Stressful life experiences facilitate responsive-
ness to psychostimulant drugs. While there is ample
evidence that adrenal glucocorticoids mediate these effects
of stress, the role of the sympatho-adrenal system in the
effects of psychostimulants is poorly understood.
Objectives The present study investigated the role of the two
adrenal stress hormones, corticosterone and epinephrine, in
sensitization to the locomotor stimulant effects of cocaine.
Materials and methods The DBA/2 mouse strain was used,
as behavioral sensitization in this strain critically depends on
adrenal hormones. Animals were subjected to adrenalectomy
(“ADX”, surgical removal of the adrenals) or SHAM surgery,
and ADX mice were given replacement of epinephrine (5×
10
−3 mg/kg subcutaneously (s.c.) just prior to each drug
administration), corticosterone (20%, s.c., pellet), or both.
Mice were subjected to a cocaine sensitization regimen
(15.0 mg/kg cocaine on nine consecutive days followed by a
7.5 mg/kg cocaine challenge after a 5-day withdrawal).
Results In agreement with our previous observations, ADX
prevented initiation and expression of cocaine-induced loco-
motor sensitization. Whereas neither corticosterone nor
epinephrine alone were sufficient to reverse the ADX effect,
both hormones were necessary to fully restore initiation and
retentionofsensitizationtolevelsobservedinSHAManimals.
Conclusions The present findings indicate that corticosterone
and epinephrine cooperate to facilitate behavioral responsive-
ness to cocaine. These data emphasize that in addition to the
hypothalamic–pituitary–adrenalaxis,thesympatheticnervous
system plays a critical role in psychostimulant sensitivity.
Keywords Corticosterone.HPAaxis.Adrenalectomy.
Sympatheticnervoussystem.Psychostimulant.Stress.
Brain.Locomotion
Abbreviations
ADX Adrenalectomy
ANOVA Analysis of variance
ANS Autonomic sympathetic nervous system
CORT Corticosterone
COC Cocaine
EPI Epinephrine
GR Glucocorticoid receptor
HPA axis Hypothalamic–pituitary–adrenal axis
RIA Radioimmunoassay
SAL Saline
SHAM Sham surgery
Introduction
It is well known that stress, resulting in activation of the
hypothalamic–pituitary–adrenal axis (HPA-axis) and the au-
tonomic sympathetic nervous system (ANS; De Kloet et al.
2005), can increase sensitivity to the behavioral and
reinforcing effects of psychostimulant drugs, a phenomenon
known as behavioral sensitization (Piazza and Le Moal 1998;
Goeders 2003). Studies in laboratory rodents have demon-
strated that stress facilitates acquisition and relapse of
psychostimulant self-administration (Piazza et al. 1990;
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Miczek 1997) and enhances sensitivity to the locomotor
stimulant properties of these drugs (Herman et al. 1984; Sorg
and Kalivas 1991; Deroche et al. 1995; Haile et al. 2001;
Lepsch et al. 2005).
A wealth of data indicates that adrenal glucocorticoids,
the output hormones of the HPA-axis, mediate the effects of
stress on psychostimulant responsiveness (Marinelli and
Piazza 2002; Goeders 2002; Deroche-Gamonet et al. 2003;
De Jong and De Kloet 2004) primarily via their actions in
the mesencephalic dopamine system (Piazza and Le Moal
1996). By contrast, the role of the ANS in psychostimulant
sensitivity has received little attention. This is surprising
since catecholamines (epinephrine, norepinephrine) are
rapidly released into the general circulation during stress
and in response to psychostimulant administration (Chiueh
and Kopin 1978). Although the catecholamines are not
likely to cross the blood–brain barrier due to their polar
structure (Weil-Malherbe et al. 1959), substantial evidence
indicates that peripheral epinephrine can alter brain func-
tion and behavior indirectly by activating vagal afferents to
the central nervous system (Gold and Van Buskirk 1975;
Borrell et al. 1983; Sternberg et al. 1985; Miyashita and
Williams 2006). Indeed, it has been shown that in addition
to their independent actions, the HPA and ANS components
of the stress response can interact to regulate behavior
(Borrell et al. 1984; Roozendaal et al. 1996).
We have previously identified a mouse strain, the DBA/2
strain, in which sensitization to the locomotor stimulant
effects of cocaine is critically dependent on adrenal hormones
(De Jong et al. 2007). Interestingly, whereas surgical removal
of the adrenals (adrenalectomy, “ADX”) prevented initiation
and expression of psychomotor sensitization, replacement of
corticosterone to concentrations similar or even higher than
those induced by stress was not sufficient to fully reverse the
effects of ADX (De Jong and De Kloet 2009). Similarly, it
has recently been reported that glucocorticoids are necessary,
but not sufficient, to restore the effects of stress on escalation
of cocaine self-administration (Mantsch and Katz 2007)a n d
on morphine-induced conditioned place preference (Der-
Avakian et al. 2006) in ADX rats. In addition, there is
considerable controversy in literature regarding the necessity
of adrenal glucocorticoids in psychostimulant-induced be-
havioral sensitization (Rivet et al. 1989; Badiani et al. 1995;
Pauly et al. 1993;P r a s a de ta l .1996;P r z e g a l i n s k ie ta l .
2000). Additional evidence for a dissociation between
corticosterone secretion and behavioral sensitization comes
from a study by Schmidt et al. (1999) who showed that
sensitization of the corticosterone response to amphetamine
was neither necessary nor sufficient for sensitization of the
psychomotor response to the psychostimulant to occur.
Collectively, these findings suggest that adrenal glucocorti-
coids may not be “the sole players on the scene.” In view of
our findings with ADX, we propose an additional role for the
adrenal catecholamine epinephrine (De Jong et al. 2007).
In the present study, we have therefore investigated the
role of adrenal glucocorticoids and epinephrine in sensiti-
zation to the locomotor stimulant effects of cocaine in the
DBA/2 strain, which has been demonstrated to be highly
susceptible to the impact of stress on drug responsiveness
(Cabib et al. 2000). Animals were adrenalectomized or
SHAM-operated, and ADX mice were given replacement
of corticosterone (through release from a s.c. implanted
20% pellet), epinephrine (5×10
−3 mg/kg, s.c., prior to each
drug administration), or both. These doses were chosen
based on previous findings (Van den Buuse et al. 2004) and
pilot studies. The data show that the HPA-axis and the ANS
act in a coordinate fashion to facilitate behavioral sensiti-
zation of DBA/2 mice to cocaine.
Materials and methods
Animals
Male DBA/2 Rj mice were obtained from Janvier (Le Genest
Saint Isle, France) at the age of 8 weeks. Mice were housed in
groups of four in perspex cages (35×19×14 cm) with food
and water available ad libitum at a 12-h light–dark cycle
(lightsonat7 A.M.) in a temperature- (21±1°C) and humidity-
(55±5%) controlled room. Surgery was performed 2 weeks
after arrival in the animal facility. Animal experiments were
performed according to the principles of laboratory animal
care as specified in the Guidelines for the Care and Use of
Mammals in Neuroscience and Behavioral Research (Na-
tional Research Council 2003) and in accordance with the
EC Council Directive of November 1986 (86/609/EEC).
Experiments were approved by the local Committee for
Animal Health, Ethics and Research of Leiden University.
Experimental design
Animals were either adrenalectomized (ADX) or SHAM-
operated. Replacement therapies consisted of corticosterone
(ADXcort), epinephrine (ADXepi), or both (ADXcort+epi).
Mice were administered saline (SAL) or cocaine (COC)
during the treatment phase of the sensitization paradigm,
resulting in ten treatment groups: SHAM (SAL/COC), ADX
(SAL/COC), ADXcort (SAL/COC), ADXepi (SAL/COC),
and ADXcort+epi (SAL/COC).
Surgery
Animals were individually housed 1 day prior to surgery.
The cages were transported to the operating room on the
morning of the surgery where mice were allowed to recover
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of a mixture of isoflurane (3 l/min), N2O (0.8 l/min), and
O2 (0.4 l/min). Adrenalectomy was performed via the
dorsal route as described previously (De Jong et al. 2007).
SHAM animals were treated similarly with the exception of
the actual removal of the adrenals. After surgery, all
animals were given free access to 0.9% NaCl in addition
to normal drinking water. The sensitization paradigm was
started following a recovery period of 1 week. Animals
were single-housed during the entire paradigm.
Drugs
Cocaine hydrochloride (BUFA Pharmaceuticals B.V., Uit-
geest, The Netherlands) was dissolved in sterile saline and
administered intraperitoneally (i.p.) in a dosage of 7.5 or
15.0 mg/kg. Corticosterone pellets (100 mg; w × h,9 ×
2 mm) consisted of 20% corticosterone (ICN Biomedicals
Inc, Aurora, Ohio, USA) in cholesterol vehicle (cholesterol
95% stabilized, Acros Organics, Geel, Belgium) and were
implanted subcutaneously in the flank of the animal 1 day
prior to the onset of the sensitization paradigm. Epinephrine
((−)-epinephrine(+)-bitartrate salt; Sigma-Aldrich Chemie
B.V., Zwijndrecht, The Netherlands) was dissolved in
sterile saline, adjusted to pH 5, and administered subcuta-
neously (s.c.) in a dosage of 5×10
−3 mg/kg just prior to
drug treatment on days 1–9, 14, and 15. Control groups
were implanted with 100% cholesterol pellets and received
equal volumes of saline instead of cocaine or epinephrine.
Sensitization paradigm
The sensitization paradigm consisted of a treatment phase
(days 1–9), a withdrawal interval (days 10–14), a saline
challenge (day 14), and two cocaine challenges (days 15
and 21). The treatment phase consisted of i.p. injections of
15.0 mg/kg cocaine (COC) or saline (SAL) on nine
consecutive days and locomotion was measured on days 1,
5, and 9. On these days, animals received the treatment in
the test setting, whereas on the remaining days, injections
were given in the home cage. The treatment period was
followed by a withdrawal interval of 5 days (no treatment).
On the last day of the withdrawal interval (day 14), all
animals received a saline challenge, and on day 15, all
animals received a 7.5 mg/kg cocaine challenge. To
investigate drug responsiveness in absence of epinephrine,
animals were re-challenged with 7.5 mg/kg cocaine 1 week
after the initial cocaine challenge (day 21) without prior
epinephrine substitution. For this day, only data of cocaine-
treated mice are presented, as the saline-treated groups
received cocaine for the second time and can therefore no
longer be considered proper controls for an acute cocaine
response. All injections were given 2 to 5 h after lights on.
Measurement and analysis of locomotor activity
All behavioral tests (days 1, 5, 9, 14, 15 and 21) were
performedintheroomwhereanimalswerehoused.Micewere
placed in a test cage (same type and size (35×19×14 cm) as
the home cage) containing a standardized amount of sawdust,
covered with a perspex lid. Following a 2-h habituation
period, animals were injected and activity was monitored on
videofor30min.Attheendofthisperiod,abloodsamplewas
taken from the tail vein for endocrine measurements and the
animals were returned to their home cage. Video images were
digitized and analyzed using Ethovision Videotracking,
Motion Analysis & Behavior Recognition System version
1.96 (“VTMAS”, Noldus Information Technology B.V.,
Wageningen, The Netherlands). The position of the animal
was sampled five times per second. Locomotion was defined
as movement with a minimal distance of 2 cm. Data are
represented in total distance moved (cm) over the entire
treatment period.
Corticosterone assay
Blood samples were taken from the tail vein by a small
incision with a razor blade 30 min after drug treatment on
test days 1, 5, 9, 14, and 15 and collected in small EDTA-
coated tubes (Microvette DB 200 K3E, Sarstedt, Nüm-
brecht, Germany). On day 21, animals were killed 30 min
after treatment and trunk blood was collected in large
EDTA-coated tubes (tube 10 ml, 95×16.8 mm, K3E,
Sarstedt). Plasma was obtained by centrifugation at
13,000 rpm for 20 min at 4°C and subsequently stored at
−20°C. Corticosterone concentrations were determined by
in duplo measurement using a radioimmunoassay (RIA) kit
from MP Biomedicals according to the protocol provided
by the manufacturer (Corticosterone double antibody
125I
RIA kit, MP Biomedicals, Asse-Relegem, Belgium). All
samples were analyzed in one assay to exclude inter-assay
variability. ADX effectively attenuated corticosterone re-
lease to basal concentrations.
Statistics
Statistical analysis was performed using SPSS for Windows
software (release 7.5, SPSS Benelux B.V., Gorinchem, The
Netherlands). Overall locomotor activity and corticosterone
data were subjected to repeated measures analysis of
variance (ANOVA) with three between-subject factors
(surgery, substitution, and treatment) and one within-
subject factor (test day). Subsequent analyses were per-
formed per test day: three-factor ANOVA for surgery,
substitution, and treatment. Whenstatistical significancewas
revealed, post hoc tests were performed (least significant
difference (LSD) or, for within subject comparison, paired t
Psychopharmacology (2009) 204:693–703 695test). Differences were considered statistically significant
when p<0.05.
Results
Effect of corticosterone and epinephrine on behavioral
sensitization in ADX mice
Main effects were found for treatment, surgery, substitution,
day, and interactions between these factors (F(treatment)]1,126=
39.878, p<0.001; F(surgery)1,126=6.667, p<0.05; F(substitu-
tion)3,126=3.006, p<0.05; F(day)5,630=28.002, p<0.001;
F(day × substitution)15,630=1.726, p<0.05, and F(day ×
treatment)5,630=14.038, p<0.001).
Figure1 depicts locomotor responses of the SHAM (SAL/
COC), ADX (SAL/COC), ADXcort (SAL/COC), ADXepi
(SAL/COC), and ADXcort+epi (SAL/COC) groups on
days 1 and 5 of the treatment period. Corticosterone
replacement via the 20% pellet reduced the initial cocaine
response (p<0.001 vs. SHAM, p<0.05 vs. ADX and
ADXepi), while there was a strong tendency for epinephrine
to reverse this effect (ADXcort vs. ADXcort+epi, p=0.060).
In addition, cocaine responses on day 1 were highest in the
SHAM group (F(treatment)1,150=13.131, p<0.001; F(sur-
gery)1,150=2.342, p=0.128; F(substitution)3,150=0.317, p=
0.813, post hoc: at least p<0.05 vs. all other treatment
groups).
As described previously (De Jong et al. 2007), SHAM
mice displayed an increase in drug responsiveness during the
treatment period (day 5 vs. day 1, p<0.05, paired t test),
whereas this was prevented by ADX (p=0.191,pairedt test).
Furthermore, cocaine responses on day 5 were reduced in
ADX when compared to SHAM mice (p<0.01). Co-
replacement of corticosterone and epinephrine fully restored
initiation of sensitization (day 5 vs. day 1, p<0.001, paired t
test) and drug responses on day 5 to the level observed in
SHAM mice. The ADXcort and ADXepi groups also
displayed an increase in cocaine responsiveness from day 1
to day 5 (p<0.01, paired t test), but drug responses on day 5
were not different from those of ADX mice and lower than
in the SHAM and ADXcort+epi groups (F(treatment)1,142=
41.974, p<0.001; F(surgery)1,142=2.870, p=0.093; F(substi-
tution)3,142=2.373, p=0.073, post hoc: at least p<0.05 vs.
SHAM and ADXcort+epi).
Drug responses on day 9 of the treatment period showed a
similargroupdistributionandwerenotfurtherenhancedwhen
compared to day 5, indicating that behavioral sensitization
develops during the first half of the treatment period (SHAM:
7,508±1,009; ADX: 4,193±725; ADXcort: 5,641±747;
ADXepi: 5,718±898; ADXcort+epi: 6,252±1,030). On this
day, there was a tendency for cocaine responses of ADXcort
and ADXepi mice to exceed those of ADX mice, but this did
not reach statistical significance (p=0.208 and p=0.195 vs.
ADX, respectively) (F(treatment)1,139=43.477, p<0.001;
F(surgery)1,139=2.390, p=0.125; F(substitution)3,139=0.425,
p=0.735).
Figure 2 depicts locomotor responses to the first cocaine
challenge on day 15. Cocaine-treated SHAM mice displayed
hyperresponsiveness to the 7.5 mg/kg cocaine challenge (p<
0.01 vs. SHAM/SAL), whereas this was not observed in ADX
mice receiving no substitution or either corticosterone or
epinephrine alone. By contrast, sensitization was restored in
ADX mice receiving co-replacement of corticosterone and
epinephrine (ADXcort+epi COC vs. SAL, p<0.05). Further-
more, drug responses of cocaine-treated SHAM and ADXcort
+epi mice were higher than of ADX and ADXepi mice
(at least p<0.05, except SHAM/COC vs. ADXepi/COC,
p=0.078), but not different from ADXcort mice [F(treat-
ment)1,138=8.182, p<0.01; F(surgery)1,138=0.644, p=0.424;
F(substitution)3,138=1.401, p=0.245). Similar group differ-
ences were observed on day 21, when cocaine-treated mice
were re-challenged with 7.5 mg/kg cocaine without prior
epinephrine substitution (Fig. 3). SHAM and ADXcort+epi
mice displayed cocaine responses higher than of ADX
and ADXepi mice (at least p<0.05), but not different
from the ADXcort mice (F(treatment)1,139=6.156, p<0.05;
F(surgery)1,139=10.867, p<0.01; F(substitution)3,139=6.186,
p<0.01).
Remarkably, responses to the saline challenge on day 14
showed a similar distribution as to the cocaine challenges on
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Fig. 1 Initiation of behavioral sensitization. Locomotion in response
to treatment on days 1 and 5 of the treatment period in which mice
received daily administration of cocaine (15.0 mg/kg) or saline.
Animals were SHAM-operated or adrenalectomized (ADX), and ADX
mice received either no substitution or replacement with corticoste-
rone (ADXcort), epinephrine (ADXepi), or both (ADXcort+epi). Data
are represented in average total distance moved (TDM, cm)±SEM, n=
7–9 (saline) or 17–24 (cocaine) animals/group.
#at least p<0.05 vs.
SHAM,
Φp<0.05 vs. ADX,
∅p<0.05 vs. ADXepi,
$at least p<0.01 vs.
ADXcort+epi (LSD),
†at least p<0.05 vs. day 1 (paired t test)
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ADXcort, and ADXcort+epi mice thanfor ADX and ADXepi
mice (SHAM: 2,496±259; ADX: 1,429±114; ADXcort:
2,597±208; ADXepi: 1,477±154; ADXcort+epi: 2,582±
239). A significant effect of treatment was only found in the
SHAM group (F(treatment)1,139=3.130, p=0.079; F(sur-
gery)1,139=2.969, p=0.087; F(substitution)3,139=4.062, p<
0.01, post hoc: SHAM COC vs. SAL, p<0.05). Locomotor
responses to the saline challenge were, however, markedly
lower than to the cocaine challenge on day 15, indicating
that conditioned responsiveness cannot have accounted for
the full sensitization as observed in response to the cocaine
challenges.
Effect of ADX and hormone replacement on plasma
corticosterone
Table 1 shows the effects of ADX and hormone replacement
on plasma corticosterone concentrations 30 min after treat-
ment on days 1, 5, 9, 14, and 15. Main effects were found for
treatment, surgery, substitution, day, and interactions between
these factors (F(treatment)1,108=30.233, p<0.001; F(sur-
gery)1,108=94.276, p<0.001; F(substitution)3,108=129.940,
p<0.001; F(day)5,540=141.546, p<0.001; F(day × substitu-
tion)15,540=105.773, p<0.001; and F(day × surgery ×
treatment)5,540=4.936, p<0.001).
Corticosterone concentrations were attenuated in the ADX
and ADXepi groups compared to the SHAM group on all test
days (at least p<0.01, except ADX/SAL day 1: p=0.058;
day 14: p=0.073; ADXepi/SAL day 1: p=0.055; day 14: p=
0.070 vs. SHAM/SAL). Cocaine-treated SHAM mice
exhibited enhanced corticosterone secretion on day 5 com-
pared to day 1 of the treatment period (p<0.001, paired t
test), with no further increase on day 9, indicating that also
endocrine sensitization develops during the first half of the
treatment period. In addition, corticosterone secretion in
response to the saline challenge on day 14 was augmented in
SHAM/COC mice (p<0.001 vs. SHAM/SAL). A similar
effect was observed in response to the cocaine challenge on
day 15, but this did not reach statistical significance (p=
0.248). In two previous studies with the exact same
paradigm, however, significantly augmented corticosterone
secretion was demonstrated in cocaine-treated SHAM mice
on day 15, suggesting that sensitization of the corticosterone
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Fig. 2 Expression of behavioral sensitization (day 15). Locomotion in
response to the 7.5 mg/kg cocaine challenge on day 15. Animals were
SHAM-operated or adrenalectomized (ADX), and ADX mice received
either no substitution or replacement with corticosterone (ADXcort),
epinephrine (ADXepi), or both (ADXcort+epi). Previously, mice
received daily administrations of 15.0 mg/kg cocaine or saline (days 1–
9), followed by a 5-day withdrawal interval and a saline challenge
(day 14). Data are represented in average total distance moved (TDM,
cm)±SEM, n=7–11 (saline) or 17–22 (cocaine) animals/group. *at
least p<0.05 vs. SAL,
#p<0.05 vs. SHAM,
$at least p<0.05 vs.
ADXcort+epi (LSD)
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Fig. 3 Expression of behavioral sensitization (day 21). Locomotion of
cocaine-treated mice in response to the second 7.5 mg/kg cocaine
challenge on day 21. On this day, epinephrine replacement was
omitted. Previously, SHAM-operated and ADX mice receiving either
no substitution or replacement with corticosterone (ADXcort), epi-
nephrine (ADXepi), or both (ADXcort+epi) were given daily admin-
istrations of 15.0 mg/kg cocaine or saline (days 1–9), followed by a
5-day withdrawal interval, a saline challenge (day 14), and a 7.5-mg/
kg cocaine challenge (day 15). Data are represented in average total
distance moved (TDM,c m ) ± S E M ,n=7–12 (saline) or 17–22
(cocaine) animals/group.
#p<0.01 vs. SHAM,
Φp<0.01 vs. ADXcort,
$p<0.001 vs. ADXcort+epi (LSD)
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et al. 2007; De Jong and De Kloet 2009).
In animals with corticosterone pellets (ADXcort and
ADXcort+epi), hormone concentrations were elevated
above SHAM levels on day 1 (p<0.001) and thereafter
gradually declined to on average 90 ng/ml on day 15, being
higher than in ADX and ADXepi mice (p<0.05), but in the
case of cocaine treatment, lower than in SHAM mice (p<
0.01). On day 21, there was no longer a difference between
ADX animals substituted with or without corticosterone
(data not shown). These data indicate that the subcutaneous
corticosterone pellet generated plasma corticosterone con-
centrations that were very high on the first day of the
treatment phase and thereafter declined to concentrations in
the range of those induced by stress, which remained until
the first cocaine challenge on day 15.
Discussion
The major finding emerging from the present experiments is
that in addition to corticosterone, epinephrine is necessary
for sensitization to the locomotor stimulant effects of cocaine
in DBA/2 mice. By contrast, neither corticosterone nor
epinephrine alone were sufficient to reverse the deficit of
ADX mice in psychomotor sensitization.
The present findings indicate that there is an interaction
between the HPA-axis and the ANS in the regulation of the
neuronal mechanism underlying behavioral sensitization to
cocaine. The notion that adrenal glucocorticoids and catechol-
amines can interact to regulate behavior is supported by
previous studies that describe both synergistic and antagonistic
interactions, most notably in memory processing (Borrell et al.
1984; Roozendaal et al. 1996). We show that in the case of
behavioral sensitization to cocaine, corticosterone and epi-
nephrine cooperate. Furthermore, the results suggest that the
cooperation between the two adrenal stress hormones occurs
during initiation rather than expression of cocaine-induced
behavioral sensitization in DBA/2 mice. ADX mice supple-
mented with either corticosterone, epinephrine, or both
showed an increase in the locomotor response to cocaine
between days 1 and 5, suggesting that either hormone
promotes the development of sensitization during repeated
cocaine treatment. However, presence of both hormones was
necessary to achieve full restoration of the cocaine response to
SHAM levels on day 5. Remarkably, replacement with
corticosterone and/or epinephrine was not sufficient to restore
the acute response to cocaine on day 1. It is conceivable that
the duration of the corticosteroid replacement was too short to
achieve reversal of the ADX effect on day 1, as the hormone
pellets were implanted one day prior to the first drug exposure.
In a previous study, we have observed that expression of
sensitization is independent of glucocorticoids, as the gluco-
corticoid receptor (GR) antagonist mifepristone failed to block
hyperresponsiveness to a drug challenge in animals that had
previously acquired this behavior (De Jong and De Kloet
2009). The same holds true for epinephrine, as drug responses
of mice receiving combined corticosterone and epinephrine
replacement were maintained when epinephrine was omitted
prior to the second cocaine challenge (day 21). The
observation that by the time of the second cocaine challenge
(day 21) drug responses of mice receiving chronic corticoste-
Table 1 Plasma corticosterone concentrations
Day 1 Day 5 Day 9 Day 14 Day 15
Saline challenge Cocaine challenge 1
SHAM SAL 87±14 92±20 125±30 66±11 182±13
COC 162±12* 313±15*
,† 307±20* 140±16* 209±22
ADX SAL 14±3 17±7
# 28±10
# 31±11 33±12
#
COC 15±3
# 26±5
# 36±7
# 32±5
# 33±6
#
CORT SAL 538±32
#,Ω 170±6
#,Ω 112±9
Ω 75±3
Ω 84±9
#,Ω
COC 500±24
#,Ω 179±6
#,Ω 130±8
#,Ω 86±5
#,Ω 92±9
#,Ω
EPI SAL 11±2 20±6
# 22±6
# 30±9 30±10
#
COC 15±2
# 29±4
# 39±6
# 36±6
# 38±6
#
CORT+EPI SAL 514±27
#,Ω 150±10
#,Ω 94±7
Ω 70±5
Ω 79±6
#,Ω
COC 460±26
#,Ω 174±8
#,Ω 131±9
#,Ω 83±6
#,Ω 88±8
#,Ω
Plasma corticosterone concentrations 30 min after treatment on days 1, 5, 9, 14, and 15. Animals were SHAM-operated or adrenalectomized
(ADX), and ADX mice received either no substitution or replacement with corticosterone (cort), epinephrine (epi), or both (cort+epi). Mice
received daily administrations of 15.0 mg/kg cocaine (COC) or saline (SAL; days 1–9), followed by a 5-day withdrawal interval, a saline
challenge (day 14), and a 7.5 mg/kg cocaine challenge (day 15). Data are represented in average corticosterone (ng/ml) ±SEM, n=6–11 (saline) or
17–21 (cocaine) animals/group
*p<0.001 vs. SAL,
#at least p<0.01 vs. SHAM,
Ωat least p<0.05 vs. ADX and ADXepi (LSD),
†p<0.001 vs. day 1 (paired t test)
698 Psychopharmacology (2009) 204:693–703rone mimicked those of SHAM mice suggests that while a
certain degree of sensitization develops in mice receiving
corticosterone, a longer withdrawal duration may be required
for this behavior to become expressed. By contrast, mice
substituted with only epinephrine did not show drug responses
higher than of ADX mice on day 21. These findings suggest
that of the two adrenal stress hormones, corticosterone plays
the most critical role in behavioral sensitization to cocaine,
whereas the primary effect of epinephrine is to facilitate the
actions of the glucocorticoid. It can, however, not be excluded
that the chronic corticosterone substitution also facilitated the
responsiveness to an acute administration of cocaine. Further
studies including additional control groups that are naive to
cocaine until day 21 are required to address this issue.
Furthermore, it is conceivable that during arousing tasks, such
as behavioral testing, there is substantial norepinephrine
release from sympathetic nerve terminals which may have
facilitated the actions of corticosterone. In addition, drug-
induced norepinephrine release may sensitize with repeated
cocaine administration, thereby contributing to the persistent
hyperresponsiveness of mice having received both replace-
ment therapies even when tested in the absence of epinephrine
(day 21). There is indeed evidence for sensitization of
norepinephrine release in the central nervous system associ-
ated with behavioral sensitization, which has been found to
occur in both the hypothalamus and the nucleus accumbens
(Schmidt et al. 2001; Vanderschuren et al. 1999). Neverthe-
less, the present finding of an interaction between the HPA-
axis and the ANS in cocaine sensitization may explain part of
the current controversy regarding the role of corticosterone in
behavioral responsiveness to psychostimulants (Rivet et al.
1989; Badiani et al. 1995; Pauly et al. 1993).
Interestingly, after sensitization, a saline challenge was
sufficient to induce a modest increase in locomotor activity
and plasma corticosterone levels in SHAM animals (day 14).
Although responses to the cocaine challenge on day 15 were
significantly greater, this indicates that sensitization does not
exclusively occur at a biochemical level in the motive system
but that the expectation to receive cocaine in a given
environment can induce these behavioral and endocrine
effects in intact animals. There is indeed a great body of
evidence demonstrating that drug-associated environments
can act asan occasionsetterfor the expressionof sensitization
(reviewed in Badiani and Robinson 2004). A similar trend
towards enhanced locomotor responsiveness to the saline
challenge was found in mice substituted with corticosterone
(ADX cort and ADXcort+epi) but not epinephrine alone,
suggesting that corticosterone is the adrenal hormone that
plays an important role in drug-induced conditioned loco-
motion, whereas epinephrine is not necessary for environ-
mental conditioning in psychomotor sensitization.
It is not likely that higher, or perhaps lower, doses of
epinephrine or corticosterone alone could be sufficient to fully
restore the effects of cocaine. In pilot studies, we have
investigated the effects of 5×10
−5 and 5×10
−2 mg/kg
epinephrine. Whereas the lower dose did not affect cocaine-
induced behavior, the higher dose gave similar results as
observed in the present study (inefficacy of epinephrine alone
and full reversal of sensitization in combination with
corticosterone). With respect to corticosterone, a 20%
corticosterone pellet has been demonstrated previously to
fully restore amphetamine-induced locomotion in ADX mice
(van den Buuse et al. 2004). Even higher doses of epinephrine
and corticosterone were found to negatively affect the physical
well-being of the animals and therefore not further pursued.
Behavioral sensitization to psychostimulant drugs is
mediated by the mesocorticolimbic dopamine system and
the neuronal circuitry it is embedded in (reviewed in Pierce
and Kalivas 1997; Vanderschuren and Kalivas 2000).
Corticosterone readily passes the blood–brain barrier and
the GR is highly expressed throughout the motive circuit and
the limbic system (Reul and De Kloet 1985;F u x ee ta l .
1985;H a r f s t r a n de ta l .1986). Studies using brain-specific
GR knockouts have shown that the impact of glucocorticoids
on psychostimulant sensitivity and behavioral sensitization is
mediated via the GR in the brain (Deroche-Gamonet et al.
2003; Izawa et al. 2006). Epinephrine, by contrast, is a polar
substance that cannot cross the blood–brain barrier (Weil-
Malherbe et al. 1959). Exogenous epinephrine does, how-
ever, modulate a wide variety of brain functions (e.g.,
memory storage, cortical information processing, arousal,
and attention), suggesting that the catecholamine influences
the central nervous systemindirectly.The mostprobableroute
is via the activation of vagal afferents to the nucleus of the
solitary tract resulting in the activation of central noradrener-
gic signaling (Gold and van Buskirk 1978; Williams and
McGaugh 1993; Roozendaal 2002; Miyashita and Williams
2006). In addition, it has been proposed that epinephrine
may influence brain function by increasing glucose concen-
trations in the blood (Gold et al. 1986), although this view
has been challenged (Gamaro et al. 1997).
Toinvestigatethepossibleinvolvementofglucose,wehave
established a dose–response curve for the effects of wide dose
range of epinephrine (5×10
−1,1 0
−2,1 0
−3,a n d1 0
−5 mg/kg)
on plasma glucose (data not shown). Whereas the two highest
doses increased plasma glucose in a dose-dependent manner,
this was not the case for the two lowest doses, including the
one used in the present study (5×10
−3 mg/kg). In addition,
we have measured plasma glucose 30 min after drug
treatment on test days 1, 9, 14, and 15 of the sensitization
paradigm and found no difference between epinephrine- and
saline-substituted mice on any test day (data not shown).
Similarly, combined corticosterone and epinephrine substitu-
tion did not affect plasma glucose levels when compared to
saline substitution. These observations indicate that the dose
of epinephrine that influences behavioral sensitization is
Psychopharmacology (2009) 204:693–703 699devoid of a metabolic effect and therefore excludes the
possibility that a change in glucose metabolism has contrib-
uted to the effects of epinephrine on behavioral sensitization.
We therefore hypothesize that the noradrenergic system
mediatesthe effects ofepinephrine onbehavioralsensitization
tococaine.Noradrenergicsignalingwouldthenbeexpectedto
play a critical role in behavioral sensitization to psychostimu-
lants, as epinephrine is rapidly secreted in response to these
drugs (Lewander 1968; Chiueh and Kopin 1978). In support
of this hypothesis, it has been shown that α-1 adrenergic
receptors play a role in cocaine- and amphetamine-induced
locomotion, behavioral sensitization, and reward (Drouin
et al. 2002a, b), although one study reported no effects of α-
and β-adrenergic receptor antagonists on behavioral sensiti-
zation to amphetamine or cocaine (Vanderschuren et al.
2003). The discrepancy between these studies is likely to
have originated from differences in experimental procedures,
such as, e.g., the doses of the psychostimulants (being
considerably lower in the studies of Drouin et al.), the design
of the sensitization paradigm, and the species and strain of
animals used. With respect to the design of the sensitization
paradigm, Drouin et al. used a context-dependent sensitiza-
tion setup, whereas Vanderschuren et al. used a context-
independent one. In view of the role of noradrenergic
neurotransmission in learning and memory processes, this
might indicate that norepinephrine is particularly involved in
the context-dependent aspects of psychomotor sensitization.
Additional evidence for the role of norepinephrine in
psychostimulant sensitization has come from a study by
Salomon et al. (2006) suggesting that behavioral sensitiza-
tion to amphetamine results from an uncoupling between
noradrenergic and serotonergic signaling. Taken together,
these studies point to a role for norepinephrine in psychos-
timulant sensitization, although it can of course not be
concluded whether this represents an indirect effect of
epinephrine, direct actions of cocaine on the norepinephrine
transporter, or both. In further support of the present
findings, it has been demonstrated that the adrenergic system
plays a role in the interaction between stress and drug
responsiveness, as α2-adrenoreceptor agonists block stress-
induced reinstatement of cocaine, heroin, and alcohol
seeking (Erb et al. 2000;S h a h a me ta l .2000;L ee ta l .
2005). An interesting avenue for further research would be to
compare the role of epinephrine in responsiveness to drugs
that differentially activate the peripheral and central cate-
cholamine (epinephrine and norepinephrine) systems, such
as, e.g., amphetamine and cocaine (Florin et al. 1994;P a n
et al. 2007; Vanderschuren et al. 2003).
Several brain regions are likely to be involved in the
interaction between norepinephrine and the mesocortico-
limbic dopamine system, and the presence of GRs
throughout the motive circuit suggests that glucocorticoids
can modulate this interaction at multiple levels. Evidence
exists that direct noradrenergic innervation of the ventral
tegmental area regulates dopamine release in the terminal
regions of these neurons (nucleus accumbens, prefrontal
cortex; Pan et al. 1996; Ihalainen and Tanila 2004). The
amygdala is an area of interest, as norepinephrine in this
region is of critical importance for the beneficial effects of
both epinephrine and corticosterone on memory consolida-
tion (Liang et al. 1986, 1995; Quirarte et al. 1997;
Roozendaal et al. 2006) and the amygdala provides
excitatory input to the mesocorticolimbic dopamine system
(Robinson and Beart 1988). Furthermore, norepinephrine in
the prefrontal cortex regulates amphetamine-induced re-
ward, locomotion, and mesoaccumbens dopamine release
(Blanc et al. 1994; Darracq et al. 1998; Ventura et al. 2003;
Steketee 2003), and the excitatory corticofugal projections
from the prefrontal cortex to the dopamine system are under
the control of adrenergic innervation (Marek and Aghajanian
1999; Kovacs and Hernadi 2003). Finally, the hippocam-
pus, receiving prominent noradrenergic innervation (Loy
et al. 1980), plays a role in the acute reinforcing effects of
drugs and in relapse to drug taking and also provides
excitatory input into the midbrain dopaminergic neurons
(Floresco et al. 2001).
In summary, the present data show that both the HPA-axis
and the ANS play a crucial role in long-term behavioral
sensitization to cocaine. This is an important finding since
numerous investigations have been dedicated to the role of
the HPA-axis in psychostimulant sensitization and reward,
whereas the ANS has hardly gained any attention. Further
characterization of the relationship between glucocorticoids,
epinephrine, and psychostimulant responsiveness will lead to
a better understanding of the mechanisms that underlie the
effects of stress on drug addiction.
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